Adjuvant therapy of histopathological risk factors of retinoblastoma in Europe: A survey by the European Retinoblastoma Group (EURbG)

Dittner-Moormann, Sabine; Reschke, Madlen; Abbink, Floor; Aerts, Isabelle; ATALAY, HATİCE; Fedorovna Bobrova, Nadezhda; Biewald, Eva; Brecht, Ines; Caspi, Shani; Cassoux, Nathalie; Castela, Guilherme; Diarra, Yelena; Duncan, Catriona; Ebinger, Martin; Garcia Aldana, David; Hadjistilianou, Doris; Kepak, Tomas; Klett, Artur; KIRATLI, HAYYAM; Maka, Erika; Opocher, Enrico; Pawinska-Wasikowska, Katarzyna; Rascon, Jelena; Russo, Ida; Rutynowska-Pronicka, Olga; Sabado alvarez, Constantino; Pacheco, Sonsoles; Svojgr, Karel; Timmermann, Beate; Vishnevskia-Dai, Vicktoria; Eggert, Angelika; Ritter-Sovinz, Petra; Bechrakis, Nikolaos; Jenkinson, Helen; Moll, Annette; Munier, Francis; Popovic, Maja; Chantada, Guillermo; Doz, Francois; Ketteler, Petra

doi:10.1002/pbc.28963

Adjuvant therapy of histopathological risk factors of retinoblastoma in Europe: A survey by the European Retinoblastoma Group (EURbG)

Atıf İçin Kopyala

Dittner-Moormann S., Reschke M., Abbink F. C. H., Aerts I., ATALAY H. T., Fedorovna Bobrova N., ...Daha Fazla

PEDIATRIC BLOOD & CANCER, cilt.68, sa.6, 2021 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 68 Sayı: 6
Basım Tarihi: 2021
Doi Numarası: 10.1002/pbc.28963
Dergi Adı: PEDIATRIC BLOOD & CANCER
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, Biotechnology Research Abstracts, CAB Abstracts, CINAHL, EMBASE, MEDLINE, Veterinary Science Database
Anahtar Kelimeler: biomarker, chemotherapy, childhood cancer, metastasis, radiotherapy, RB1 gene
Gazi Üniversitesi Adresli: Evet

Özet

Introduction Advanced intraocular retinoblastoma can be cured by enucleation, but spread of retinoblastoma cells beyond the natural limits of the eye is related to a high mortality. Adjuvant therapy after enucleation has been shown to prevent metastasis in children with risk factors for extraocular retinoblastoma. However, histological criteria and adjuvant treatment regimens vary and there is no unifying consensus on the optimal choice of treatment.